Literature DB >> 21816711

Renal complications in multiple myeloma and related disorders: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Beth M Faiman1, Patricia Mangan, Jacy Spong, Joseph D Tariman.   

Abstract

Kidney dysfunction is a common clinical feature of symptomatic multiple myeloma. Some degree of renal insufficiency or renal failure is present at diagnosis or will occur during the course of the disease and, if not reversed, will adversely affect overall survival and quality of life. Chronic insults to the kidneys from other illnesses, treatment, or multiple myeloma itself can further damage renal function and increase the risk for additional complications, such as anemia. Patients with multiple myeloma who have light chain (Bence Jones protein) proteinuria may experience renal failure or progress to end-stage renal disease (ESRD) and require dialysis because of light chain cast nephropathy. Kidney failure in patients with presumed multiple myeloma also may result from amyloidosis, light chain deposition disease, or acute tubular necrosis caused by nephrotoxic agents; therefore, identification of patients at risk for kidney damage is essential. The International Myeloma Foundation's Nurse Leadership Board has developed practice recommendations for screening renal function, identifying positive and negative contributing risk and environmental factors, selecting appropriate therapies and supportive care measures to decrease progression to ESRD, and enacting dialysis to reduce and manage renal complications in patients with multiple myeloma.

Entities:  

Mesh:

Year:  2011        PMID: 21816711      PMCID: PMC3433942          DOI: 10.1188/11.CJON.S1.66-76

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  49 in total

1.  Managing myeloma kidney.

Authors:  Morie A Gertz
Journal:  Ann Intern Med       Date:  2005-12-06       Impact factor: 25.391

2.  Erythropoiesis-stimulating agents--time for a reevaluation.

Authors:  Ellis F Unger; Aliza M Thompson; Melanie J Blank; Robert Temple
Journal:  N Engl J Med       Date:  2010-01-06       Impact factor: 91.245

Review 3.  Multiple myeloma: diagnosis and treatment.

Authors:  S Vincent Rajkumar; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2005-10       Impact factor: 7.616

Review 4.  Influence of the parathyroid glands on bone metabolism.

Authors:  H H Malluche; N Koszewski; M C Monier-Faugere; J P Williams; H Mawad
Journal:  Eur J Clin Invest       Date:  2006-08       Impact factor: 4.686

5.  Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial.

Authors:  William F Clark; A Keith Stewart; Gail A Rock; Marion Sternbach; David M Sutton; Brendan J Barrett; A Paul Heidenheim; Amit X Garg; David N Churchill
Journal:  Ann Intern Med       Date:  2005-12-06       Impact factor: 25.391

6.  Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia.

Authors:  Frank Bridoux; Christophe Sirac; Valérie Hugue; Catherine Decourt; Antoine Thierry; Nathalie Quellard; Ramzi Abou-Ayache; Jean-Michel Goujon; Michel Cogné; Guy Touchard
Journal:  Am J Kidney Dis       Date:  2005-04       Impact factor: 8.860

Review 7.  Renal, hematologic and infectious complications in multiple myeloma.

Authors:  Joan Bladé; Laura Rosiñol
Journal:  Best Pract Res Clin Haematol       Date:  2005       Impact factor: 3.020

8.  The cost of chronic dialysis in multiple myeloma.

Authors:  R A Coward
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

9.  Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution.

Authors:  J Bladé; P Fernández-Llama; F Bosch; J Montolíu; X M Lens; S Montoto; A Cases; A Darnell; C Rozman; E Montserrat
Journal:  Arch Intern Med       Date:  1998-09-28

10.  Single versus double autologous stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Thierry Facon; François Guilhot; Chantal Doyen; Jean-Gabriel Fuzibet; Mathieu Monconduit; Cyrille Hulin; Denis Caillot; Reda Bouabdallah; Laurent Voillat; Jean-Jacques Sotto; Bernard Grosbois; Regis Bataille
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

View more
  4 in total

1.  Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Teresa S Miceli; Kathleen Colson; Beth M Faiman; Kena Miller; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

Review 2.  From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma.

Authors:  David S Siegel
Journal:  Ther Adv Hematol       Date:  2013-12

Review 3.  Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.

Authors:  Monica Epstein; Candis Morrison
Journal:  Semin Oncol       Date:  2022-02-10       Impact factor: 5.385

4.  Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment in Multiple Myeloma.

Authors:  Jia-Hong Chen; Shun-Neng Hsu; Tzu-Chuan Huang; Yi-Ying Wu; Chin Lin; Ping-Ying Chang; Yeu-Chin Chen; Ching-Liang Ho
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.